Freedom Broker: biopharmaceutical company Latigo Biotherapeutics completes IPO

Latigo Biotherapeutics debuted on Nasdaq on August 7 with a substantial funding cushion to advance pain treatments. The company increased the size of its IPO to $345.6 million and priced the shares at the top of the initial range — $18 per share.

Latigo Biotherapeutics bets on non-opioid pain relief

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing medicines to treat acute and chronic pain without the use of opioids. At the core of its platform are inhibitors of the Nav1.8 sodium channel, which is involved in transmitting pain signals.

According to the company, the advantage of this approach is that it acts primarily on peripheral nerve tissue rather than the brain. This could potentially enable the development of analgesics without the opioid-associated risk of dependence.

IPO priced at the top of the range

Latigo initially planned to offer 16 million shares at $16–18. Ultimately, the company increased the offering to 19.2 million shares and set the IPO price at $18, which matches the top end of the initial range. The amount raised totaled $345.6 million before underwriting costs. The company’s market capitalization is estimated at about $1.3 billion. The company’s shares will trade under the ticker LTGO.

Flagship asset — LTG-001

Latigo’s leading candidate is LTG-001, an oral Nav1.8 inhibitor for treating moderate-to-severe acute pain, including postoperative pain.

Freedom Broker experts note that the company recently reported positive preliminary results from a study involving 343 patients who underwent abdominoplasty. LTG-001 met the study’s primary endpoint — SPID48 (which measures the analgesic effect after the first dose) versus placebo.

In the second half of 2026, Latigo plans to launch a placebo-controlled Phase III study in patients with hallux valgus, as well as an open-label Phase III study to assess the drug’s safety in a broader population of acute-pain patients, the analysts note. Preliminary results are expected in the second half of 2027.

Second drug targets chronic pain

The second key candidate, LTG-321, is also a Nav1.8 inhibitor and is being developed to treat chronic musculoskeletal pain, starting with osteoarthritis. The drug is already in Phase II clinical trials. The study is being conducted in patients with knee osteoarthritis and is designed for approximately 120 participants. 

The IPO market is expanding

The U.S. IPO market is gradually picking up. The brand Tailored Brands (MENW), one of North America’s largest specialty menswear retailers, completed an IPO. The company operates more than 1,000 stores under the Men's Wearhouse, Jos. A. Bank, Moores, and K&G Fashion Superstore brands. In July, Tailored Brands filed for an IPO on Nasdaq, but the offering terms have not yet been disclosed.

Also coming to market is Apnimed (APMD), a biopharmaceutical company developing an oral therapy for obstructive sleep apnea. The company planned to raise about $150 million by pricing shares at $14–16, with an implied post-IPO valuation of about $569.8 million.

In June, Reformation (REF) also went public — a U.S. womenswear manufacturer and retailer focused on sustainable fashion. The company offered 14.06 million shares at $15–17, aiming to raise about $225 million at an estimated market cap of roughly $945.2 million. In fiscal 2025, Reformation’s revenue rose to $507.1 million from $438.2 million a year earlier, although net profit fell to $12.6 million from $33 million.

Not an individual investment recommendation.